Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (17824)	1/16/1999 10:52:00 AM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

frostman...nothing new with this statement...VVUS IR has said the same international orders are going to be lower in qtr 4 over qtr 3. We know Viagra has been introduced into the same marketspace in qtr 4. But we are also hearing that the inital falloff in Muse sales is recovered to much better percentages than in the USA. Other comments that have been made along the way ...are that ASTRA and Janssen feel it's better to introduce MUSE in a new marketspace after Viagra has been launched. Then go after the Viagra failures and patients that should not use Viagra due to safety issues. This should not be a problem going forward since Viagra launch in new countries is now ahead of MUSE. Just as we are seeing a rise in scripts in the USA without a partner on word of mouth that MUSE is an alternative to Viagra. A marketing partner in the USA will be much more successful. ASTRA and Janssen will push the safety issue and use the ACC/AHA report to it's advantage. We are now just beginning to see reports of Viagra users overseas deaths. I expect the UK NHS to be very causious in their Viagra guidelines that are expected to be issued soon.